A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence

NCT07009470 · clinicaltrials.gov ↗

NA

Phase

ACTIVE_NOT_RECRUITING

Status

130

Enrollment

OTHER

Sponsor class

Conditions

HCC

Interventions

DRUG: Finotonlimab (an anti-PD-1 monoclonal antibody) and Anbeizhu (a bevacizumab biosimilar)
PROCEDURE: TACE

Sponsor

Tongji Hospital